Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2017, Article ID 1951628, 5 pages
Research Article

QT and QTc in Male Patients with Psychotic Disorders Treated with Atypical Neuroleptics

Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Correspondence should be addressed to Mario Miniati; ti.ipinu.dem@itainim.oiram

Received 21 March 2017; Revised 5 June 2017; Accepted 11 June 2017; Published 12 July 2017

Academic Editor: Rajesh R. Tampi

Copyright © 2017 Mario Miniati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. Beach, C. M. Celano, P. A. Noseworthy, J. L. Januzzi, and J. C. Huffman, “QTc Prolongation, Torsades de Pointes, and Psychotropic Medications,” Psychosomatics, vol. 54, no. 1, pp. 1–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. F. T. Khasawneh and G. S. Shankar, “Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia,” Cardiology Research and Practice, vol. 2014, Article ID 273060, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. J. M. Straus, G. S. Bleumink, J. P. Dieleman et al., “Antipsychotics and the risk of sudden cardiac death,” Archives of Internal Medicine, vol. 164, no. 12, pp. 1293–1297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhytmic Potential for Non-Antiarrhythmic Drugs. October 2005 ICH.
  5. G. S. Wagner, P. Macfarlane, H. Wellens et al., “AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology,” Journal of the American College of Cardiology, vol. 53, no. 11, pp. 1003–1011, 2009. View at Publisher · View at Google Scholar
  6. R. W. Piepho, “Cardiovascular effects of antipsychotics used in bipolar illness,” Journal of Clinical Psychiatry, supplement 4, pp. 20–23, 2002. View at Google Scholar
  7. P. M. Haddad and I. M. Anderson, “Antipsychotic-related QTc prolongation, torsade de pointes and sudden death,” Drugs, vol. 62, no. 11, pp. 1649–1671, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. Sudden Arrhytmia Death Syndromes Foundation, “An overview of the inherited long QT syndrome,” July 31, 2001. Available at html. Accessed Jan 14, 2002.
  9. K. Hatta, T. Takahashi, H. Nakamura, H. Yamashiro, and Y. Yonezawa, “Prolonged QT interval in acute psychotic patients,” Psychiatry Research, vol. 94, no. 3, pp. 279–285, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. World Medical Association, “World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects,” JAMA, vol. 310, no. 20, pp. 2191–2194, 2013. View at Publisher · View at Google Scholar
  11. E. Poluzzi, E. Raschi, A. Koci et al., “Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting system database,” Drug Safety, vol. 36, no. 6, pp. 467–479, 2013. View at Publisher · View at Google Scholar · View at Scopus